Reflections on the early development of poxvirus vectors

Vaccine

Volumn 31, Issue 39, 2013, Pages 4220-4222

  Moss, Bernard ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

DNA cloning; Recombinant DNA; Recombinant vaccines; Vaccine vectors; Vaccinia virus

Indexed keywords

POXVIRUS VECTOR; RECOMBINANT DNA; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; BACTERIOPHAGE T7; EXPRESSION VECTOR; HOMOLOGOUS RECOMBINATION; INFLUENZA; MALARIA; MOLECULAR CLONING; NEOPLASM; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; TRANSCRIPTION TERMINATION; TUBERCULOSIS; VACCINIA VIRUS; VIRUS GENOME; VIRUS RECOMBINANT;

DNA CLONING; RECOMBINANT DNA; RECOMBINANT VACCINES; VACCINE VECTORS; VACCINIA VIRUS;

ANIMALS; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; POXVIRIDAE; VACCINES, DNA; VACCINIA VIRUS;

EID: 84882850376     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.03.042     Document Type: Article

References (63)

1. Jackson D.A., Symons R.H., Berg P. Biochemical method for inserting new genetic information into DNA of simian virus 40: circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli. Proc Natl Acad Sci USA 1972, 69:2904-2909.
2. Wittek R., Barbosa E., Cooper J.A., Garon C.F., Chan H., Moss B. Inverted terminal repetition in vaccinia virus DNA encodes early mRNAs. Nature 1980, 285:21-25.
3. Wittek R., Cooper J., Barbosa E., Moss B. Expression of the vaccinia virus genome - analysis and mapping of mRNAs encoded within the inverted terminal repetition. Cell 1980, 21:487-493.
4. Baroudy B.M., Venkatesan S., Moss B. Incompletely base-paired flip-flop terminal loops link the two DNA strands of the vaccinia virus genome into one uninterrupted polynucleotide chain. Cell 1982, 28:315-324.
5. Goebel S.J., Johnson G.P., Perkus M.E., Davis S.W., Winslow J.P., Paoletti E. The complete DNA sequence of vaccinia virus. Virology 1990, 179:247-266. 517-63.
6. Yang Z., Bruno D.P., Martens C.A., Porcella S.F., Moss B. Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing. Proc Natl Acad Sci USA 2010, 107:11513-11518.
7. Yang Z., Reynolds S.E., Martens C.A., Bruno D.P., Porcella S.F., Moss B. Expression profiling of the intermediate and late stages of poxvirus replication. J Virol 2011, 85:9899-9908.
8. Woodroofe G.M., Fenner F. Genetic studies with mammalian poxviruses, IV. Hybridization between several different poxviruses. Virology 1960, 12:272-282.
9. Nakano E., Panicali D., Paoletti E. Molecular genetics of vaccinia virus: demonstration of marker rescue. Proc Natl Acad Sci USA 1982, 79:1593-1596.
10. Weir J.P., Bajszar G., Moss B. Mapping of the vaccinia virus thymidine kinase gene by marker rescue and by cell-free translation of selected mRNA. Proc Natl Acad Sci USA 1982, 79:1210-1214.
11. Wittek R., Cooper J.A., Moss B. Transcriptional and translational mapping of a 6.6-kilobase-pair DNA fragment containing the junction of the terminal repetition and unique sequence at the left end of the vaccinia virus genome. J Virol 1981, 39:722-732.
12. Mackett M., Smith G.L., Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA 1982, 79:7415-7419.
13. Panicali D., Paoletti E. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci USA 1982, 79:4927-4931.
14. Smith G.L., Mackett M., Moss B. Infectious vaccinia virus recombinants that express hepatitis B antigen. Nature 1983, 302:490-495.
15. Smith G.L., Murphy B.R., Moss B. Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci USA 1983, 80:7155-7159.
16. Moss B., Smith G.L., Gerin J.L., Purcell R.H. Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature 1984, 311:67-69.
17. Panicali D., Davis S.W., Weinberg R.L., Paoletti E. Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci USA 1983, 80:5364-5368.
18. Paoletti E., Lipinskas B.R., Samsonoff C., Mercer S.R., Panicali D. Construction of live vaccines using gentically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci USA 1984, 81:193-197.
19. Mackett M., Smith G.L., Moss B. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol 1984, 49:857-864.
20. Esposito J.J., Knight J.C., Shaddock J.H., Novembre F.J., Bauer G.M. Successful oral rabies vaccination of raccoons with raccoon poxvirus recombinants expressing rabies virus glycoprotein. Virology 1988, 167:313-316.
21. Boyle D.B., Coupar B.E.H. Construction of recombinant fowlpox viruses as vectors for poultry vaccines. Virus Res 1988, 10:343-356.
22. Taylor J., Weinberg R., Languet B., Desmettre P., Paoletti E. Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine 1988, 6:497-503.
23. Jackson R.J., Bults H.G. A myxoma virus intergenic transient dominant selection vector. J Gen Virol 1992, 73:3241-3245.
24. Hu Y., Lee J., McCart A., Xu H., Moss B., Alexander H.R., et al. Yaba-like disease virus: an alternative replicating poxvirus vector for cancer gene therapy. J Virol 2001, 75:10300-10308.
25. Marsland B.J., Tisdall D.J., Heath D.D., Mercer A.A. Construction of a recombinant orf virus that expresses an Echinococcus granulosus vaccine antigen from a novel genomic insertion site. Arch Virol 2003, 148:555-562.
26. Wiktor T.J., Macfarlan R.I., Reagan K.J., Dietzschold B., Curtis P., Wunner W.H., et al. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc Natl Acad Sci USA 1984, 81:7194-7198.
27. Rupprecht C.E., Wiktor T.J.A., Johnston D.H., Hamir A.N., Dietzschold B., Wunner W.H., et al. Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine. Proc Natl Acad Sci USA 1986, 83:7947-7950.
28. Taylor J., Trimarchi C., Weinberg R., Languet B., Guillemin F., Desmettre P., et al. Efficacy studies on a canarypox-rabies recombinant virus. Vaccine 1991, 9:190-193.
29. Boyle D.B. Quantitative assessment of poxvirus promoters in fowlpox and vaccinia virus recombinants. Virus Genes 1992, 6:281-290.
30. Tartaglia J., Perkus M.E., Taylor J., Norton E.K., Audonnet J.C., Cox W.I., et al. NYVAC - a highly attenuated strain of vaccinia virus. Virology 1992, 188:217-232.
31. Stickl H., Hochstein-Mintzel V., Mayr A., Huber H.C., Schäfer H., Holzner A. MVA-stufenimpfung gegen pocken. klinische erprobung des attenuierten pocken-lebendimpfstoffes, stamm MVA (MVA vaccination against smallpox: clinical trials of an attenuated live vaccinia virus strain (MVA). Dtsch Med Wochenschr 1974, 99:2386-2392.
32. Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 1992, 89:10847-10851.
33. Sutter G., Wyatt L.S., Foley P.L., Bennink J.R., Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994, 12:1032-1040.
34. Ober B.T., Bruhl P., Schmidt M., Wieser V., Gritschenberger W., Coulibaly S., et al. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara. J Virol 2002, 76:7713-7723.
35. Moss B. Poxviridae: the viruses and their replication. Fields virology 2007, 2905-2946. Lippincott Williams & Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
36. Davison A.J., Moss B. New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins. Nucleic Acids Res 1990, 18:4285-4286.
37. Chakrabarti S., Sisler J.R., Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 1997, 23:1094-1097.
38. Wyatt L.S., Shors S.T., Murphy B.R., Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 1996, 14:1451-1458.
39. Earl P.L., Hügin A.W., Moss B. Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus. J Virol 1990, 64:2448-2451.
40. Gomez C.E., Perdiguero B., Najera J.L., Sorzano C.O.S., Jimenez V., Gonzalez-Sanz R., et al. Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J Virol 2012, 86:5026-5038.
41. Falivene J., Zajac M.P.D., Pascutti M.F., Rodriguez A.M., Maeto C., Perdiguero B., et al. Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. Plos One 2012, 7:e32220.
42. Wyatt L.S., Earl P.L., Xiao W., Americo J.L., Cotter C.A., Vogt J., et al. Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection. J Virol 2009, 83:7176-7184.
43. Falkner F.G., Moss B. Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J Virol 1988, 62:1849-1854.
44. Blasco R., Moss B. Selection of recombinant vaccinia viruses on the basis of plaque formation. Gene 1995, 158:157-162.
45. Staib C., Drexler I., Ohlmann M., Wintersperger S., Erfle V., Sutter G. Transient host range selection for genetic engineering of modified vaccinia virus Ankara. Biotechniques 2000, 28:1137-1142.
46. White S.D., Conwell K., Langland J.O., Jacobs B.L. Use of a negative selectable marker for rapid selection of recombinant vaccinia virus. Biotechniques 2011, 50:303-309.
47. Domi A., Moss B. Engineering of a vaccinia virus bacterial artificial chromosome in Escherichia coli by bacteriophage lambda-based recombination. Nat Methods 2005, 2:95-97.
48. Cottingham M.G., Andersen R.F., Spencer A.J., Saurya S., Furze J., Hill A.V.S., et al. Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS One 2008, 3:e1638.
49. Fuerst T.R., Earl P.L., Moss B. Use of a hybrid vaccinia virus T7 RNA polymerase system for expression of target genes. Mol Cell Biol 1987, 7:2538-2544.
50. Ward G.A., Stover C.K., Moss B., Fuerst T.R. Stringent chemical and thermal regulation of recombinant gene expression by vaccinia virus vectors in mammalian cells. Proc Natl Acad Sci USA 1995, 92:6773-6777.
51. Schnell M.J., Mebatsion T., Conzelmann K-K. Infectious rabies viruses from cloned cDNA. EMBO J 1994, 13:4195-4204.
52. Lawson N.D., Stillman E.A., Whitt M.A., Rose J.K. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci USA 1995, 92:4477-4481.
53. Collins P.L., Hill M.G., Camargo E., Grossfeld H., Chanock R.M., Murphy B.R. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci USA 1995, 92:11563-11567.
54. Yilma T., Anderson K., Brechling K., Moss B. Expression of an adjuvant gene (interferon-gamma) in infectious vaccinia virus recombinants. Vaccines 87 modern approaches to vaccines: prevention of AIDS and other viral, bacterial, and parasitic diseases 1987, 393-396. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. R.M. Chanock, R.A. Lerner, F. Brown, H. Ginsberg (Eds.).
55. Ramshaw A., Andrew M.E., Phillips S.M., Boyle D.B., Coupar B.E.H. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature 1987, 329:545-546.
56. Flexner C., Hugin A., Moss B. Prevention of vaccinia virus infection in immunodeficient nude mice by vector-directed IL-2 expression. Nature 1987, 330:259-262.
57. Gherardi M.M., Ramirez J.C., Rodriguez D., Rodriguez J.R., Sano G.I., Zavala F., et al. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner. J Immunol 1999, 162:6724-6733.
58. Oh S., Berzofsky J.A., Burke D.S., Waldmann T.A., Perera L.P. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc Natl Acad Sci USA 2003, 100:3392-3397.
59. Miyahira Y., Garcia-Sastre A., Rodriguez D., Rodriguez J.R., Murata K., Tsuji M., et al. Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice. Proc Natl Acad Sci USA 1998, 95:3954-3959.
60. Anderson R.J., Hannan C.M., Gilbert S.C., Laidlaw S.M., Sheu E.G., Korten S., et al. Enhanced CD8(+) T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus. J Immunol 2004, 172:3094-3100.
61. Walther M., Thompson F.M., Dunachie S., Keating S., Todryk S., Berthoud T., et al. Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein. Infect Immun 2006, 74:2706-2716.
62. Schneider J., Gilbert S.C., Blanchard T.J., Hanke T., Robson K.J., Hannan C.M., et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998, 4:397-402.
63. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001, 292:69-74.